Medical Information
United States
 

In order to provide you with relevant and meaningful content we need to know more about you.

Please choose the category that best describes you.

Información selecta para pacientes y cuidadores que se encuentra disponible en Español.

This content is intended for U.S. Healthcare Professionals. Would you like to proceed?

If you provide additional keywords, you may be able to browse through our database of Scientific Response Documents.

Our scientific content is evidence-based, scientifically balanced and non-promotional. It undergoes rigorous internal medical review and is updated regularly to reflect new information.

rocuronium bromide injection Highlights

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use ROCURONIUM BROMIDE INJECTION safely and effectively. See full prescribing information for ROCURONIUM BROMIDE INJECTION.
ROCURONIUM BROMIDE injection solution for intravenous use
Initial U.S. Approval: 1994

RECENT MAJOR CHANGES

Dosage and Administration
  Important Dosing and Administration Information (2.1)07/2018
Warnings and Precautions
  Risk of Death due to Medication Errors (5.3) 07/2018

INDICATIONS AND USAGE

Rocuronium bromide injection is a nondepolarizing neuromuscular blocking agent indicated as an adjunct to general anesthesia to facilitate both rapid sequence and routine tracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation. (1)

DOSAGE AND ADMINISTRATION

To be administered only by experienced clinicians or adequately trained individuals supervised by an experienced clinician familiar with the use, actions, characteristics, and complications of neuromuscular blocking agents. (2.1)

Individualize the dose for each patient. (2.1)
Peripheral nerve stimulator recommended for determination of drug response and need for additional doses, and to evaluate recovery. (2.1)
Store rocuronium bromide with cap and ferrule intact and in a manner that minimizes the possibility of selecting the wrong product. (2.1)
Tracheal intubation: Recommended initial dose is 0.6 mg/kg. (2.2)
Rapid sequence intubation: 0.6 to 1.2 mg/kg. (2.3)
Maintenance doses: Guided by response to prior dose, not administered until recovery is evident. (2.4)
Continuous infusion: Initial rate of 10 to 12 mcg/kg/min. Start only after early evidence of spontaneous recovery from an intubating dose. (2.5)

DOSAGE FORMS AND STRENGTHS

5 mL multiple dose vials containing 50 mg rocuronium bromide injection (10 mg/mL). (3)
10 mL multiple dose vials containing 100 mg rocuronium bromide injection (10 mg/mL). (3)

CONTRAINDICATIONS

Hypersensitivity (e.g., anaphylaxis) to rocuronium bromide or other neuromuscular blocking agents. (4)

WARNINGS AND PRECAUTIONS

Appropriate Administration and Monitoring: Use only if facilities for intubation, mechanical ventilation, oxygen therapy, and an antagonist are immediately available. (5.1)
Anaphylaxis: Severe anaphylaxis has been reported. Consider cross-reactivity among neuromuscular blocking agents. (5.2)
Risk of Death due to Medication Errors: Accidental administration can cause death. (5.3)
Need for Adequate Anesthesia: Must be accompanied by adequate anesthesia or sedation. (5.4)
Residual Paralysis: Consider using a reversal agent in cases where residual paralysis is more likely to occur. (5.5)

ADVERSE REACTIONS

Most common adverse reactions (2%) are transient hypotension and hypertension. (6)

To report SUSPECTED ADVERSE REACTIONS, contact Hospira, Inc. at 1-800-441-4100 or electronically at [email protected], or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

DRUG INTERACTIONS

Succinylcholine: Use before succinylcholine has not been studied. (7.11)
Nondepolarizing muscle relaxants: Interactions have been observed. (7.7)
Enhanced rocuronium bromide injection activity possible: Inhalation anesthetics (7.3), certain antibiotics (7.1), quinidine (7.10), magnesium (7.6), lithium (7.4), local anesthetics (7.5), procainamide (7.8)
Reduced rocuronium bromide injection activity possible: Anticonvulsants. (7.2)

USE IN SPECIFIC POPULATIONS

Labor and Delivery: Not recommended for rapid sequence induction in patients undergoing Cesarean section. (8.2)
Pediatric Use: Onset time and duration will vary with dose, age, and anesthetic technique. Not recommended for rapid sequence intubation in pediatric patients. (8.4)

See 17 for PATIENT COUNSELING INFORMATION.

Revised: 3/2019

Did you find an answer to your question? Yes No
Didn’t find what you were looking for? Contact us.
Report Adverse Event